Published: 10 November 2022
Author(s): Wern Yew Ding, Marco Proietti, Giulio Francesco Romiti, Marco Vitolo, Ameenathul Mazaya Fawzy, Giuseppe Boriani, Francisco Marin, Carina Blomström-Lundqvist, Tatjana S. Potpara, Laurent Fauchier, Gregory Y. H Lip, ESC-EHRA EORP-AF Long-Term General Registry Investigators
Issue: January 2023
Section: Original article

Atrial fibrillation (AF) is a significant public health issue with a global prevalence of 33.5 million patients affected by the condition and approximately 5 million new cases identified each year [1]. The number of patients with AF are increasing, with projections of a surge in incidence and prevalence by 63% and 66%, respectively, over the next 30 years [2]. The significance of AF is characterised by major contribution to excess morbidity and mortality [3–5], as well as increasing healthcare cost [6].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.